Literature DB >> 8533445

[Thrombomodulin is a marker of microvascular, but not for macrovascular endothelial cell damage].

T Sernau1, C Wilhelm, U Seyfert, S Gabath, M Henkels, J Amiral, K H Bergis, R Ziegler, P Wahl, P P Nawroth.   

Abstract

UNLABELLED: Plasma levels of thrombomodulin are increased in diseases associated with microangiopathia. The target of this study was to examine whether plasma thrombomodulin is also influenced by macroangiopathia. There was no variation of plasma thrombomodulin in a sample of 183 diabetic patients with or without peripheral arterio-occlusive disease of the lower limbs. In a second sample of 33 patients with peripheral arteriosclerosis of the lower limbs, without any indication of diabetes, plasma levels of thrombomodulin were not significantly increased compared to a control group. Since thrombomodulin is also found in thrombocytes, we analysed whether plasma thrombomodulin levels were influenced by platelet activation. Neither platelet activation after hyperthermal limb perfusion not the PGE1-treatment showed any effect on plasma thrombomodulin level.
CONCLUSION: Thrombomodulin is a marker for microvascular but not for macrovascular endothelial cell damage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8533445

Source DB:  PubMed          Journal:  Vasa        ISSN: 0301-1526            Impact factor:   1.961


  3 in total

1.  The Relationship between Endothelial Dysfunction and Endothelial Cell Markers in Peripheral Arterial Disease.

Authors:  Kimihiro Igari; Toshifumi Kudo; Takahiro Toyofuku; Yoshinori Inoue
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

2.  miR-499 released during myocardial infarction causes endothelial injury by targeting α7-nAchR.

Authors:  Rui Zhou; Wenjun Huang; Xinrong Fan; Feng Liu; Liangqin Luo; Haiyang Yuan; Yu Jiang; Haiying Xiao; Zhichao Zhou; Chenliang Deng; Xitong Dang
Journal:  J Cell Mol Med       Date:  2019-07-03       Impact factor: 5.310

Review 3.  The Evolving Concept of Neuro-Thromboinflammation for Neurodegenerative Disorders and Neurotrauma: A Rationale for PAR1-Targeting Therapies.

Authors:  Barry W Festoff; Chris Dockendorff
Journal:  Biomolecules       Date:  2021-10-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.